Influence of IL10 (G1082A) and TNFα (G308A) Polymorphisms on the Survival of Pediatric Patients with ALL

Abstract

Interleukin 10 (IL10) is a pleiotropic cytokine that stimulates various hematopoietic cells. The tumor necrosis factor alpha (TNFα) is a cytokine that may influence the transcriptional activity induced by glucocorticoids. This study examined the impact of TNFα (G308A) and IL10 (G1082A) polymorphisms at promoter regions in relation to the overall survival of 105 children (0 ≤ 18 years) with acute lymphoblastic leukemia (ALL) for a period of 126 months, treated according to the protocol GBTLI99. The G1082A and G308A polymorphisms were identified by allele-specific PCR and PCR-RFLP, respectively. Patients with IL10AA genotype had a higher death ratio (44%, P = 0.0089). Patients with both IL10AA and TNFAA genotypes showed the worst survival when compared with the IL10GG and TNFGA genotypes (P = 0.0043). The results of this study revealed a lower survival among patients with IL10AA genotype and the concomitant occurrence of IL10AA and TNFAA genotypes.

TGFβ and IL10 have an impact on risk group and prognosis in childhood ALL

“…For IL10, disease‐specific distribution differences have already been described in leukaemia. Comparable to our results, in acute myeloic leukaemia (AML) differences referred of the IL10 promoter gene polymorphism at position −592 and −819 and in ALL at position −1082 have been described . In our cohort, we investigated these three single nucleotide polymorphisms in the promoter of the IL10 gene (−1082, −819 and −592) and showed that the IL10 high‐producer haplotype GCC/GCC was less frequent in ALL patients than in healthy controls .…”

Cytokine gene polymorphism [tumor necrosis factor-alpha (–308), IL-10 (–1082), IL-6 (–174), IL-17F, 1RaVNTR] in pediatric patients with primary immune thrombocytopenia and response to different treatment modalities

“…This finding was also suggested in the study of de Deus et al [36] who showed that IL-10 GG genotype might have a lower risk for prednisone poor response in childhood acute lymphoblastic leukemia.…”

IL-10 gene polymorphism and influence of chemotherapy on cytokine plasma levels in childhood acute lymphoblastic leukemia patients

“…It is known that rs1800896 polymorphism, within the IL-10 gene promoter region, might influence IL-10 expression and plasma levels [37,38]. It was described that G-allele carrier patients have a better response to ALL treatment which includes glucocorticoids, leading to a better outcome [39,40] A C C E P T E D M A N U S C R I P T…”